Literature DB >> 29500277

Sequencing Pancreatic Juice: Squeezing the Most Out of Surveillance.

Matthew B Lipner1,2, Jen Jen Yeh3,2,4.   

Abstract

Next-generation sequencing of pancreatic juice can detect and quantify tumor-promoting mutations, supporting imaging and cytology findings to predict the degree of dysplasia in patients at high risk for pancreatic cancer. Future studies are needed to optimize this approach and determine how it best fits into clinical practice. Clin Cancer Res; 24(12); 2713-5. ©2018 AACRSee related article by Suenaga et al., p. 2963. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Year:  2018        PMID： 29500277      PMCID： PMC6295911          DOI： 10.1158/1078-0432.CCR-18-0215

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  5 in total

1.  International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas.

Authors:  Masao Tanaka; Carlos Fernández-del Castillo; Volkan Adsay; Suresh Chari; Massimo Falconi; Jin-Young Jang; Wataru Kimura; Philippe Levy; Martha Bishop Pitman; C Max Schmidt; Michio Shimizu; Christopher L Wolfgang; Koji Yamaguchi; Kenji Yamao
Journal:  Pancreatology       Date:  2012-04-16       Impact factor: 3.996

2.  Pancreatic Juice Mutation Concentrations Can Help Predict the Grade of Dysplasia in Patients Undergoing Pancreatic Surveillance.

Authors:  Masaya Suenaga; Jun Yu; Koji Shindo; Koji Tamura; Jose Alejandro Almario; Christopher Zaykoski; P Dane Witmer; Shahriar Fesharakizadeh; Michael Borges; Anne-Marie Lennon; Eun-Ji Shin; Marcia Irene Canto; Michael Goggins
Journal:  Clin Cancer Res       Date:  2018-01-04       Impact factor: 12.531

3.  KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound.

Authors:  James R Eshleman; Alexis L Norris; Yoshihiko Sadakari; Marija Debeljak; Michael Borges; Colleen Harrington; Elaine Lin; Aaron Brant; Thomas Barkley; J Alejandro Almario; Mark Topazian; James Farrell; Sapna Syngal; Jeffrey H Lee; Jun Yu; Ralph H Hruban; Mitsuro Kanda; Marcia Irene Canto; Michael Goggins
Journal:  Clin Gastroenterol Hepatol       Date:  2014-12-04       Impact factor: 11.382

4.  Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection.

Authors:  Chanjuan Shi; Noriyoshi Fukushima; Tadayoshi Abe; Yansong Bian; Li Hua; Brian J Wendelburg; Charles J Yeo; Ralph H Hruban; Michael G Goggins; James R Eshleman
Journal:  Cancer Biol Ther       Date:  2008-03       Impact factor: 4.742

5.  International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer.

Authors:  Marcia Irene Canto; Femme Harinck; Ralph H Hruban; George Johan Offerhaus; Jan-Werner Poley; Ihab Kamel; Yung Nio; Richard S Schulick; Claudio Bassi; Irma Kluijt; Michael J Levy; Amitabh Chak; Paul Fockens; Michael Goggins; Marco Bruno
Journal:  Gut       Date:  2012-11-07       Impact factor: 23.059
  5 in total
  1 in total

1.  An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer.

Authors:  Chun-Hao Pan; Yuka Otsuka; BanuPriya Sridharan; Melissa Woo; Cindy V Leiton; Sruthi Babu; Mariana Torrente Gonçalves; Ryan R Kawalerski; Ji Dong K Bai; David K Chang; Andrew V Biankin; Louis Scampavia; Timothy Spicer; Luisa F Escobar-Hoyos; Kenneth R Shroyer
Journal:  Mol Oncol       Date:  2020-07-04       Impact factor: 6.603
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.